Evidence map›Paper›PMID 30021700›Full record

ArticleThe lancet. HIV2018

Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey.

Ayesha B M Kharsany, Cherie Cawood, David Khanyile, Lara Lewis, Anneke Grobler, Adrian Puren, Kaymarlin Govender, Gavin George, Sean Beckett, Natasha Samsunder and 6 more

Open access · greenAbstract read
In one paragraph

Article in The lancet. HIV, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Ayesha B M KharsanyCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. Electronic address: Ayesha.Kharsany@caprisa.org.
Cherie CawoodEpicentre AIDs Risk Management (Pty) Limited, Cape Town, South Africa.
David KhanyileEpicentre AIDs Risk Management (Pty) Limited, Cape Town, South Africa.
Lara LewisCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Anneke GroblerCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Adrian PurenCentre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service (NICD/NHLS), Johannesburg, South Africa.
Kaymarlin GovenderHealth Economics and HIV and AIDS Research Division (HEARD), University of KwaZulu-Natal, Durban, South Africa.
Gavin GeorgeHealth Economics and HIV and AIDS Research Division (HEARD), University of KwaZulu-Natal, Durban, South Africa.
Sean BeckettHealth Economics and HIV and AIDS Research Division (HEARD), University of KwaZulu-Natal, Durban, South Africa.
Natasha SamsunderCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Savathree MaduraiGlobal Clinical and Virology Laboratory, Amanzimtoti, South Africa.
Carlos ToledoCenters for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Zawadi ChipetaCenters for Disease Control and Prevention (CDC), Pretoria, South Africa; BroadReach, Cape Town, South Africa.
Mary GlenshawCenters for Disease Control and Prevention (CDC), Pretoria, South Africa.
Sara HerseyCenters for Disease Control and Prevention (CDC), Pretoria, South Africa; Centers for Disease Control and Prevention (CDC), Freetown, Sierra Leone.
Quarraisha Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, NY, USA.
University of KwaZulu-Natal · ZACentre for the AIDS Programme of Research in South Africa · ZAEpicentre (South Africa) · ZABroadReach Healthcare (South Africa) · ZACenters for Disease Control and Prevention · USNational Health Laboratory Service · ZA

Funding

Identifying sources of HIV infection in adolescent girls in rural South AfricaR01HD083343 · NICHD · CENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA · PI KHARSANY, AYESHA BM, KOHLER, HANS-PETER · 2015 to 2019
$1.7M
CGH CDC HHS U2G GH000372Intramural CDC HHS CC999999NICHD NIH HHS R01 HD083343PEPFAR
6 · The paper itself

Abstract

backgroundIn high HIV burden settings, maximising the coverage of prevention strategies is crucial to achieving epidemic control. However, little is known about the reach and effect of these strategies in some communities.

methodsWe did a cross-sectional community survey in the adjacent Greater Edendale and Vulindlela areas in the uMgungundlovu district, KwaZulu-Natal, South Africa. Using a multistage cluster sampling method, we randomly selected enumeration areas, households, and individuals. One household member (aged 15-49 years) selected at random was invited for survey participation. After obtaining consent, questionnaires were administered to obtain sociodemographic, psychosocial, and behavioural information, and exposure to HIV prevention and treatment programmes. Clinical samples were collected for laboratory measurements. Statistical analyses were done accounting for multilevel sampling and weighted to represent the population. A multivariable logistic regression model assessed factors associated with HIV infection.

findingsBetween June 11, 2014, and June 22, 2015, we enrolled 9812 individuals. The population-weighted HIV prevalence was 36·3% (95% CI 34·8-37·8, 3969 of 9812); 44·1% (42·3-45·9, 2955 of 6265) in women and 28·0% (25·9-30·1, 1014 of 3547) in men (p<0·0001). HIV prevalence in women aged 15-24 years was 22·3% (20·2-24·4, 567 of 2224) compared with 7·6% (6·0-9·3, 124 of 1472; p<0·0001) in men of the same age. Prevalence peaked at 66·4% (61·7-71·2, 517 of 760) in women aged 35-39 years and 59·6% (53·0-66·3, 183 of 320) in men aged 40-44 years. Consistent condom use in the last 12 months was 26·5% (24·1-28·8, 593 of 2356) in men and 22·7% (20·9-24·4, 994 of 4350) in women (p=0·0033); 35·7% (33·4-37·9, 1695 of 5447) of women's male partners and 31·9% (29·5-34·3, 1102 of 3547) of men were medically circumcised (p<0·0001), and 45·6% (42·9-48·2, 1251 of 2955) of women and 36·7% (32·3-41·2, 341 of 1014) of men reported antiretroviral therapy (ART) use (p=0·0003). HIV viral suppression was achieved in 54·8% (52·0-57·5, 1574 of 2955) of women and 41·9% (37·1-46·7, 401 of 1014) of men (p<0·0001), and 87·2% (84·6-89·8, 1086 of 1251) of women and 83·9% (78·5-89·3, 284 of 341; p=0·3670) of men on ART. Age, incomplete secondary schooling, being single, having more than one lifetime sex partner (women), sexually transmitted infections, and not being medically circumcised were associated with HIV-positive status.

interpretationThe HIV burden in specific age groups, the suboptimal differential coverage, and uptake of HIV prevention strategies justifies a location-based approach to surveillance with finer disaggregation by age and sex. Intensified and customised approaches to seek, identify, and link individuals to HIV services are crucial to achieving epidemic control in this community.

fundingThe President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention.

Indexed as

Family CharacteristicsPublic HealthAdolescentAdultCD4 Lymphocyte CountCross-Sectional StudiesEpidemicsFemaleHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisPrevalenceRisk FactorsSexual Partners

Identifiers

PMID30021700
PMCPMC7498647
OpenAlexW2884876183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.